Therefore, RA patients with treatment failure are characterized by a persistent inflammatory status due to high concentrations of acute-phase reactants (CRP and ESR), proinflammatory cytokines (IL-1, IL-6, TNF-α), and autoantibodies (ACPAs, RF) [10,41,42]. The gene discussed is IL6; the disease is rheumatoid arthritis.